Table 3.
Studies reporting outcome data
| Sl no. | Author/year | Treatment Groups | VAS score | WOMAC | Lequesne Score | Knee Range of Motion | TUG | 6-MWT | Adverse events | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
||||||||||
| Base line | End point | Base line | End point | Base line | End point | Base line | End point | Base line | End point | Base line | End point | ||||
| 1 | Crowley et al. 2009 [11] | UC-II | NR | 40% Reduction | NR | 33% Reduction | NR | 15% Reduction | NR | NR | NR | NR | NR | 35 | |
| G+C | NR | 15% Reduction | NR | 14% Reduction | NR | 6% Reduction | NR | NR | NR | NR | NR | 58 | |||
| 2 | Lugo et al. 2016 [13] | UC-II | 58.4±0.99 | Significant Decrease UC-II vs. placebo | 58.1±1.03 | 24.0±1.23 Reduction in mean WOMAC | 7.90±0.13 | UC-II versus placebo (2.9 vs. 2.1), UC-II versus GC (2.9 vs. 2.2) | 114±1.57 | NR | NR | NR | NR | ||
| 22.5±1.20 | |||||||||||||||
| GC | 59.1±0.97 | NR | 57.5±1.33 | 19.2±1.20 | 8.02±0.12 | 114±1.36 | NR | NR | NR | NR | |||||
| Placebo control | 58.2±0.97 | NR | 56.9±1.36 | 17.0±1.25 | 7.74±0.12 | 114±1.62 | NR | NR | NR | NR | |||||
| 3. | Bakilan et al. 2016 [14] | AC+CII | 4 (0-9) | 2 (0-10) | 53.5 (29-98) | 44 (24-89) | NR | NR | NR | NR | NR | NR | NR | NR | |
| AC | 3 (0-8) | 3 (0-8) | 50 (28-103) | 52 (24-102) | NR | NR | NR | NR | NR | NR | |||||
| 4 | Costa et al. 2020 [15] | CPG | 6.42±1.68 | 3.26±2.88 | 45.25±17.88 | 24.11±24.5 | 11.18±3.30 | 7.08±5.97 | 117.1±13.71-R | 124.00±14.13 | 11.53±3.51 | 9.24±3.91 | 301.38±92.21 | 372.10±145.04 | NR |
| 114.85±14.42-L | 124.42±12.64-L | ||||||||||||||
| PCPG | 5.60±2.11 | 3.05±2.82 | 43.00±20.21 | 27.05±24.76 | 11.20±3.45 | 8.75±6.30 | 118.80±17.06-R | 120.30±14.68 | 11.56±4.26 | 9.93±3.14 | No | NR | |||
| 122.00±16.88-L | 122.50±14.20-L | significant change | |||||||||||||
| 5 | Costa et al. 2021 [16] | CG | NR | NR | 34.9±16.2 | 15.8±15.8 | 9.6±2.6 | 4.7±4.1 | NR | 8.88±2.60 | 8.01±2.61 | 325.4±71.7 | 371.0±70.6 | NR | |
| Placebo control | NR | NR | 34.9±20.6 | 29.7±20.1 | 10.7±5.0 | 9.4±6.0 | NR | 11.28±4.99 | 11.04±4.34 | 308.2±89.67 | 309.6±88.8 | NR | |||
| 6 | Rui et al. 2021 [9] | UC-II | 3.43±1.9 | 2.11±1.6 | 56.02±12.1 | 36.00±7.6 | NR | NR | 57.9 ±14.0 | 66.9±10.4 | NR | NR | NR | NR | |
| Placebo control | 3.10±1.98 | 2.91±2.3 | 50.12±10.1 | 47.61±7.6 | NR | NR | 51.8±15.2 | 52.4±10.7 | NR | NR | NR | NR | |||
| 7 | Sadigursky et al. 2022 [17] | UC-II | 7.1±0.9 | 3.4±1.6 | 54.0±16.6 | 44.6±12.0 | NR | NR | NR | NR | NR | NR | NR | ||
| Control | 7.3±0.7 | 6.0±1.8 | 58.6±14.3 | 57.3±16.5 | NR | NR | NR | NR | NR | NR | NR | ||||
| 8 | Santana et al. 2022 [18] | UC-II | NR | NR | 55.6±3.6 | 38.0±6.3 | NR | NR | 105.4±5.4 | 113.4±3.6 | 7.5±0.2 | 6.6±0.1 | 403.8±12.5 | 445.7±10.3 | NR |
| Control | NR | NR | 60.4±4.8 | 51.1±4.7 | NR | NR | 100.0±3.7 | 97.8±3.4 | 12.1±0.7 | 2±0.3 | 316.1±21.0 | 334.8±13.2 | NR | ||
| EG | NR | NR | 48.4±6.4 | 26.2±6.3 | NR | NR | 102.7±4.1 | 110.0±3.7 | 12.4±1.1 | 7.9±0.5 | 344.7±23.7 | 407.4±16.3 | NR | ||
VAS-Visual Analog Scale, WOMAC-Western Ontario and McMaster Universities, NR-Not Reported, TUG-Timed Up and Go test, 6MWT-6-minute walk test, R-Right Knee, L-Left Knee.